ClariTrial — AI Clinical Trial Intelligence

Explore/PROTAC degrader Phase 1 recruiting

Status

Phase

4 results for “PROTAC degrader Phase 1 recruiting”

NCT04606446

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 1Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants41 sites · United States, Australia, ChinaCompletes Feb 2028

CT.gov Full analysis →

NCT06964009

Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer

DT2216Paclitaxel

Elizabeth Stover, MD, PhD30 participants3 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

NCT06586957

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Solid TumorAdvanced Solid TumorSolid Tumor, Adult

NKT3964

NiKang Therapeutics, Inc.150 participants19 sites · United StatesCompletes Jan 2029

CT.gov Full analysis →

NCT06620302

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

CT.gov Full analysis →

1–4 of 4

Explore/PROTAC degrader Phase 1 recruiting

Status

Phase

4 results for “PROTAC degrader Phase 1 recruiting”

NCT04606446

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 1Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants41 sites · United States, Australia, ChinaCompletes Feb 2028

CT.gov Full analysis →

NCT06964009

Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer

DT2216Paclitaxel

Elizabeth Stover, MD, PhD30 participants3 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

NCT06586957

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Solid TumorAdvanced Solid TumorSolid Tumor, Adult

NKT3964

NiKang Therapeutics, Inc.150 participants19 sites · United StatesCompletes Jan 2029

CT.gov Full analysis →

NCT06620302

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

CT.gov Full analysis →

1–4 of 4